Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC4W03)

Drug Name

Premafloxacin Drug Info

Synonyms

Premafloxacin; 143383-65-7; UNII-UOM2HMO524; UOM2HMO524; CHEMBL230599; U-95376; 1-cyclopropyl-6-fluoro-8-methoxy-7-((R)-3-((S)-1-(methylamino)ethyl)pyrrolidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Premafloxacin [USAN:INN]; Premafloxacin (USAN/INN); SCHEMBL1230382; AC1L2G72; CTK4C3611; DTXSID70162407; 3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(3R)-3-[(1S)-1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-; BDBM50205462; AKOS030530871; D05605; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 71455
CAS Number: CAS 143383-65-7
TTD Drug ID: DMC4W03
VARIDT Drug ID: DR00744

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Streptococcus Topoisomerase IV A (Stre-coc parC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cetraxal Otic	DMX9K3W	Otitis externa	AA00-AA13	Phase 3	[2]
Pumiliotoxin 251D	DMY2F6T	Bacterial infection	1A00-1C4Z	Investigative	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Staphylococcus Topoisomerase IV (Stap-coc parC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[4]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[4]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[4]
Ozenoxacin	DM6KZMG	Impetigo	1B72	Approved	[5]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[4]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[4]
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[6]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[7]
Delafloxacin Meglumine	DMVTU5Q	Acute bacterial skin infection	1C41	Approved	[8]
Moxifloxacin	DMU8V4S	Bacterial infection	1A00-1C4Z	Approved	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Inhibitor	[1]
Streptococcus Topoisomerase IV A (Stre-coc parC)	TT1WJCI	PARC_STRPN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7.
2	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.
3	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
6	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.